This multi-center Italian prospective observational study reports the 4 months follow-up data of 87 patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) shifted from intravenous to subcutaneous immunoglobulin treatment. A therapeutic shift from intravenous to subcutaneous immunoglobulin was performed in 87 patients (66 CIDP; 21 MMN) affected by immune-mediated peripheral neuropathies with evidence of a sustained clinical response to intravenous immunoglobulin. Patients were evaluated by means of the Overall Neuropathy Limitation Scale, Medical Research Council Scale and Life Quality Index questionnaire, both at the time of therapeutic shift and after 4 months of subcutaneous immunoglobulin treatment. A sustained clinical efficacy was observed after the switch to subcutaneous immunoglobulin: the Overall Neuropathy Limitation Scale score improved in the group of 66 CIDP patients (P = 0.018), with only one subject reporting a worsening of 1 point, and remained stable in the group of 21 MMN patients (P = 0.841), with one subject reporting a worsening of two points. An improvement in the patient's perception of therapeutic setting was reported in both groups. This large multi-center study confirms the short-term clinical equivalence of subcutaneous versus intravenous immunoglobulin and a possible improvement in the patient's perception of therapeutic setting with the subcutaneous administration. However, further studies are required to extend the results to a longer observational period.

Cocito, D., Merola, A., Peci, E., Mazzeo, A., Fazio, R., Francia, A., et al. (2014). Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. JOURNAL OF NEUROLOGY, 261(11), 2159-2164 [10.1007/s00415-014-7444-2].

Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study

MARFIA, GIROLAMA ALESSANDRA;
2014

Abstract

This multi-center Italian prospective observational study reports the 4 months follow-up data of 87 patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) shifted from intravenous to subcutaneous immunoglobulin treatment. A therapeutic shift from intravenous to subcutaneous immunoglobulin was performed in 87 patients (66 CIDP; 21 MMN) affected by immune-mediated peripheral neuropathies with evidence of a sustained clinical response to intravenous immunoglobulin. Patients were evaluated by means of the Overall Neuropathy Limitation Scale, Medical Research Council Scale and Life Quality Index questionnaire, both at the time of therapeutic shift and after 4 months of subcutaneous immunoglobulin treatment. A sustained clinical efficacy was observed after the switch to subcutaneous immunoglobulin: the Overall Neuropathy Limitation Scale score improved in the group of 66 CIDP patients (P = 0.018), with only one subject reporting a worsening of 1 point, and remained stable in the group of 21 MMN patients (P = 0.841), with one subject reporting a worsening of two points. An improvement in the patient's perception of therapeutic setting was reported in both groups. This large multi-center study confirms the short-term clinical equivalence of subcutaneous versus intravenous immunoglobulin and a possible improvement in the patient's perception of therapeutic setting with the subcutaneous administration. However, further studies are required to extend the results to a longer observational period.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26 - Neurologia
English
Con Impact Factor ISI
Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Immunoglobulins; Immunoglobulins, Intravenous; Injections, Subcutaneous; Italy; Male; Middle Aged; Motor Neuron Disease; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Prospective Studies; Time Factors; Young Adult
Cocito, D., Merola, A., Peci, E., Mazzeo, A., Fazio, R., Francia, A., et al. (2014). Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. JOURNAL OF NEUROLOGY, 261(11), 2159-2164 [10.1007/s00415-014-7444-2].
Cocito, D; Merola, A; Peci, E; Mazzeo, A; Fazio, R; Francia, A; Valentino, P; Liguori, R; Filosto, M; Siciliano, G; Clerici, A; Lelli, S; Marfia, Ga; Antonini, G; Cecconi, I; Nobile Orazio, E; Lopiano, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Subcutaneous immunoglobulin in CIDP and MMN- a short-term nationwide study.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 170.59 kB
Formato Adobe PDF
170.59 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/128465
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 57
  • ???jsp.display-item.citation.isi??? 53
social impact